United States

WIRB-Copernicus Group appoints Lindsay McNair chief medical officer

Friday, October 3, 2014 08:29 AM

WIRB-Copernicus Group (WCG), a provider of regulatory and ethical review services and software to support clinical research, has promoted Lindsay McNair, M.D., M.P.H., M.S.B., to chief medical officer.

More... »


With NIH Grant, Cedars-Sinai brings big data to neuro disease research

Thursday, October 2, 2014 02:23 PM

Investigators at the Los Angeles Cedars-Sinai Regenerative Medicine Institute have received a grant from the NIH to participate in a consortium taking the study of motor neuron disorders—such as Lou Gehrig's disease and spinal muscular atrophy—to a new, comprehensive perspective.

More... »


National MS Society invests nearly $19 million in MS research

Thursday, October 2, 2014 02:16 PM

The National Multiple Sclerosis (MS) Society has committed nearly $19 million to support an expected 54 new MS research projects. These are part of a comprehensive research strategy aimed at stopping MS, restoring function that has been lost and ending the disease forever.

More... »

Glialogix, National Multiple Sclerosis Society collaborate

Thursday, October 2, 2014 02:08 PM

Glialogix, a San Francisco Bay Area-based emerging biopharma company, has entered into a sponsored research agreement with Fast Forward, a nonprofit organization established by the New York-based National Multiple Sclerosis (MS) Society to accelerate the development of treatments for MS. Fast Forward will provide funding for preclinical studies of GLX1112, a first-in-class neuroprotective therapy designed to slow the accumulation of disability in progressive MS.

More... »

CytRx receives multiple FDA Orphan Drug designations for Aldoxorubicin

Thursday, October 2, 2014 01:50 PM

CytRx, a biopharmaceutical R&D company specializing in oncology, has announced that the FDA has granted multiple Orphan Drug designations for the company's lead drug candidate, aldoxorubicin, in three indications: glioblastoma multiforme (GBM), small cell lung cancer and ovarian cancer. Aldoxorubicin is CytRx's modified version of the widely-used chemotherapeutic agent, doxorubicin.

More... »

FDA awards grants to stimulate drug, device development for rare diseases

Wednesday, October 1, 2014 01:27 PM

The FDA has awarded 15 grants totaling more than $19 million to boost the development of medical device, drug and biological products for patients with rare diseases, with at least a quarter of the funding going to studies focused solely on pediatrics.

More... »

Clinical Conductor CTMS, OpenClinica EDC partner

Wednesday, October 1, 2014 01:17 PM

Clinical Conductor CTMS, a Rochester, N.Y.-based provider of clinical trial management system, and OpenClinica, a Waltham, Mass.-based provider of global electronic data capture (EDC) software platforms, have partnered to deliver a seamless EDC-CTMS integration to drive productivity in clinical research.

More... »

LabConnect uses custom approach to enhance clinical data mining

Wednesday, October 1, 2014 01:16 PM

LabConnect, a Seattle, Wash.-based provider of central laboratory services to the biopharmaceutical industry, has released its BioVisualization software platform.

More... »

Catalent, Cingulate Therapeutics ink agreement for new ADHD treatments

Tuesday, September 30, 2014 09:00 AM

Catalent Pharma Solutions, headquartered in Somerset, N.J., has reached an exclusive development and licensing agreement with Cingulate Therapeutics (CTx), a Morristown, N.J.-based, privately held biopharmaceutical company, to support development of a series of new prescription pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) using Catalent's OSDrC OptiDose drug delivery platform.

More... »

Novo Nordisk establishes obesity research unit in Seattle

Tuesday, September 30, 2014 08:00 AM

Novo Nordisk will establish a new obesity research unit in Seattle, Wash. The new unit is a result of Novo Nordisk's increasing focus on obesity. Its main task will be to identify novel approaches and targets for obesity treatments, while increasing the scientific understanding of existing obesity targets.

More... »

`
CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs